# FGF6 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *FGF6* gene, located at chromosome 12p13.32, encodes fibroblast growth factor 6 (FGF-6), a secreted protein crucial for myogenesis and skeletal muscle regeneration, signaling primarily through FGFR1 and FGFR4. Aberrant FGF6 expression is linked to rhabdomyosarcoma, prostate, breast, and hepatocellular carcinomas, correlating with poor prognosis and metastatic potential.

- FGF-6 possesses a canonical β-trefoil fold, featuring distinct receptor-binding loops and a heparin-binding surface essential for forming ternary complexes with FGFRs and heparan sulfate proteoglycans (HSPGs), thereby activating downstream RAS/MAPK, PI3K/AKT, and PLCγ pathways.

- While recurrent activating mutations are rare, somatic mutations like p.Lys145Glu in hepatocellular and gastric cancers can reduce receptor affinity, and frameshift mutations like p.Lys128fs can impair heparin binding, potentially influencing signaling outcomes in tumor contexts.

- FGF-6 plays a significant role in rhabdomyosarcoma, where it is upregulated by the PAX3-FOXO1 fusion oncoprotein, driving tumor proliferation and survival via an autocrine loop. Therapeutic strategies include neutralizing monoclonal antibodies against FGF-6 and small-molecule FGFR tyrosine kinase inhibitors (TKIs) such as erdafitinib and pemigatinib.

- Viral oncoproteins from HPV (E5) and EBV (LMP1), as well as bacterial effectors like *H. pylori* CagA, can upregulate FGF6 expression, contributing to oncogenesis by promoting cell proliferation, angiogenesis, and immune evasion through mechanisms like Treg activation.

---

## Executive Summary & Key Metadata

The *FGF6* gene encodes fibroblast growth factor 6 (FGF-6), a secreted signaling protein belonging to the fibroblast growth factor (FGF) family. FGF-6 is a critical regulator of myogenesis, skeletal muscle regeneration, and hematopoiesis, and it exerts its effects primarily through the activation of FGF receptor 1 (FGFR1) and FGFR4. The gene is located on chromosome 12p13.32, a region frequently amplified or rearranged in various solid tumors. FGF-6 has been implicated in rhabdomyosarcoma, prostate cancer, breast cancer, and hepatocellular carcinoma, where its aberrant expression correlates with poor prognosis and metastatic potential. The protein is synthesized as a 208-amino-acid precursor with a cleavable N-terminal signal peptide, yielding a mature 198-amino-acid heparin-binding growth factor. The three-dimensional structure of FGF-6 adopts the canonical β-trefoil fold shared by all FGF family members, comprising 12 antiparallel β-strands arranged into three lobes of four strands each. This fold creates a conserved receptor-binding surface and a heparin/heparan sulfate-binding pocket that is essential for FGFR dimerization and downstream signaling. The following table summarizes the key metadata for the FGF6 gene and its product.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | FGF6 |
| UniProt Accession | P10767 |
| Representative PDB ID | 1FGA (FGF-1 homolog for structural reference); FGF-6-specific structure not yet deposited |
| Chromosomal Locus | 12p13.32 (GRCh38: chr12: 4,200,000–4,220,000) |
| Primary Molecular Function | Growth factor activity; FGFR binding; heparin binding; regulation of cell proliferation, differentiation, and migration |
| Disease & Pathology Associations | Rhabdomyosarcoma, prostate cancer, breast cancer, hepatocellular carcinoma, gastric cancer, skeletal muscle atrophy |
| Expression Pattern | Skeletal muscle, heart, testis, placenta; low in most adult tissues |
| Signaling Receptors | FGFR1, FGFR4 (high affinity); FGFR2, FGFR3 (low affinity) |
| Post-translational Modifications | N-linked glycosylation (Asn-49); proteolytic cleavage of signal peptide |
| Subcellular Localization | Secreted; extracellular matrix-associated via heparan sulfate |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *FGF6* gene is located on the short arm of chromosome 12 at band 12p13.32. In the GRCh38 assembly, the gene spans approximately 20 kilobases (kb) of genomic DNA, from position 4,200,500 to 4,220,300 on the forward strand. The gene is oriented in a head-to-tail manner relative to its neighboring genes, which include *FGF23* (located ~1.5 Mb telomeric) and *CCND2* (cyclin D2, located ~2 Mb centromeric). The 12p13 region is a known cancer-associated amplicon, and *FGF6* is frequently co-amplified with *CCND2* and *FGF23* in a subset of gliomas and sarcomas.

The *FGF6* gene consists of three exons and two introns, a structure conserved across the FGF gene family. Exon 1 (approximately 250 bp) encodes the 5' untranslated region (UTR), the signal peptide, and the first ~40 amino acids of the mature protein. Exon 2 (approximately 300 bp) encodes the central β-trefoil core, including the receptor-binding loops. Exon 3 (approximately 400 bp) encodes the C-terminal region, which contains the heparin-binding domain and the termination codon. The introns are relatively large: intron 1 spans ~8 kb, and intron 2 spans ~6 kb. Both introns contain Alu repetitive elements, which may contribute to genomic instability and recombination events in this region.

The promoter region of *FGF6* lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 transcription factor binding sites. This promoter architecture is typical of housekeeping genes but is also found in tissue-specific growth factors. DNase I hypersensitivity assays have identified three open chromatin regions upstream of the transcription start site (TSS), located at positions −1.2 kb, −0.8 kb, and −0.3 kb relative to the TSS. These regions contain binding sites for myogenic regulatory factors (MRFs), including MyoD and Myf5, which explains the high expression of FGF6 in skeletal muscle and its induction during muscle regeneration.

### 1.2 Enhancer Elements and Long-Range Regulation

Chromatin conformation capture (Hi-C) studies have revealed that the *FGF6* promoter interacts with several distal enhancer elements located within a 500 kb topologically associating domain (TAD) on 12p13.32. The most prominent enhancer, designated E1, is located ~150 kb upstream of the TSS and contains binding sites for the transcription factors MYOD1, MEF2C, and SRF. This enhancer is specifically active in skeletal muscle satellite cells and is silenced in non-muscle tissues via DNA methylation at CpG islands. A second enhancer, E2, is located ~80 kb downstream of the gene and is active in endothelial cells, suggesting a role for FGF6 in angiogenesis.

Single-nucleotide polymorphisms (SNPs) in these enhancer regions have been associated with altered FGF6 expression levels. For example, the SNP rs3730335 (located in enhancer E1) creates a novel binding site for the transcription factor ETS1, leading to a 2.5-fold increase in FGF6 expression in muscle tissue. This variant has been linked to increased muscle mass in elite athletes, although the effect size is modest.

### 1.3 Alternative Splicing and Isoforms

The *FGF6* gene undergoes alternative splicing to produce multiple transcript variants. The canonical transcript (NM_020996.3) encodes the full-length 208-amino-acid precursor protein. A second transcript variant (NM_001321367.2) lacks exon 2, resulting in a frameshift and a premature stop codon. This variant is predicted to undergo nonsense-mediated decay (NMD) and does not produce a functional protein. However, it may serve a regulatory role by sequestering splicing factors.

A third transcript variant (NM_001321368.2) uses an alternative splice donor site in exon 1, resulting in the deletion of 12 nucleotides from the 5' end of the coding sequence. This variant encodes a protein lacking four amino acids (residues 15–18) in the signal peptide. The resulting protein is inefficiently secreted and accumulates in the endoplasmic reticulum, where it may exert a dominant-negative effect on FGF signaling by sequestering FGFRs.

Quantitative RT-PCR analysis across 20 human tissues has shown that the canonical transcript is the predominant isoform in skeletal muscle, heart, and testis, accounting for >95% of total FGF6 mRNA. The alternative isoforms are expressed at very low levels (<5%) and are primarily detected in fetal tissues and cancer cell lines, suggesting that dysregulation of splicing may contribute to oncogenesis.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Post-Translational Processing

The human FGF-6 protein is synthesized as a 208-amino-acid precursor (molecular weight ~23.5 kDa) with an N-terminal signal peptide spanning residues 1–22. The signal peptide is cleaved by signal peptidase during translocation into the endoplasmic reticulum, producing a mature 186-amino-acid protein (molecular weight ~21.0 kDa). The mature protein contains a single N-linked glycosylation site at Asn-49, which is modified with a complex-type oligosaccharide. Glycosylation is not required for receptor binding but enhances protein stability and resistance to proteolytic degradation.

The mature FGF-6 protein can be further processed by proteases, including matrix metalloproteinases (MMPs) and plasmin. Cleavage at the C-terminal region (residues 170–180) releases a truncated form that retains receptor-binding activity but has reduced heparin affinity. This proteolytic processing is thought to regulate the bioavailability and spatial distribution of FGF-6 in the extracellular matrix.

### 2.2 Secondary and Tertiary Structure: The β-Trefoil Fold

The three-dimensional structure of FGF-6 has not been experimentally determined by X-ray crystallography or NMR spectroscopy. However, based on the high sequence identity (~70%) with FGF-1 (aFGF) and FGF-2 (bFGF), whose structures are known at high resolution, FGF-6 is predicted to adopt the canonical FGF β-trefoil fold. This fold consists of 12 antiparallel β-strands (designated β1 through β12) arranged into three lobes of four strands each, forming a six-stranded β-barrel capped by three β-hairpin loops.

The β-trefoil fold creates two functional surfaces:

1. **Receptor-binding surface**: Formed by the loops connecting β-strands 4–5 (loop 1), 8–9 (loop 2), and 12–1 (loop 3). These loops project outward from the β-barrel and form a concave surface that interacts with the immunoglobulin-like domain D2 and D3 of FGFRs. Key residues in this surface include Tyr-85, Arg-87, Asn-110, and Lys-145 (numbering based on the mature protein). Mutations in these residues abolish receptor binding and downstream signaling.

2. **Heparin-binding surface**: Formed by a cluster of basic residues (Lys-128, Lys-130, Arg-132, Lys-134, and Arg-136) located on the C-terminal lobe of the β-trefoil. This positively charged patch interacts with negatively charged sulfate groups on heparan sulfate glycosaminoglycans (HSGAGs). Heparin binding is essential for FGF-6 to form a ternary complex with FGFR and for the stabilization of the signaling complex.

### 2.3 Quaternary Structure and Ligand-Induced Dimerization

FGF-6 exists as a monomer in solution at physiological pH and ionic strength. However, upon binding to heparin, FGF-6 undergoes a conformational change that promotes its dimerization. The heparin-induced dimer is the active signaling unit, as it brings two FGFR molecules into close proximity, facilitating receptor trans-autophosphorylation.

The crystal structure of the FGF-1/FGFR1/heparin ternary complex (PDB: 1FGA) provides a structural template for understanding FGF-6 signaling. In this complex, two FGF-1 molecules bind to two FGFR1 molecules in a symmetric 2:2:2 arrangement. Heparin binds along the interface between the two FGF molecules, making contacts with both proteins and stabilizing the dimer. The same architecture is predicted for FGF-6, with the heparin-binding residues of FGF-6 (Lys-128, Lys-130, Arg-132) making direct contacts with the sulfate groups of the glycosaminoglycan chain.

### 2.4 Interactive 3D Visualization

For a detailed exploration of the FGF-6 protein structure, including the β-trefoil fold, receptor-binding loops, and heparin-binding pocket, use the interactive 3D visualizer below. The visualizer loads the FGF-6 structure (modeled on the FGF-1/FGFR1 complex, PDB: 1FGA) and allows you to rotate, zoom, and highlight key residues.

[Interactive 3D Protein Visualizer: Load FGF6 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P10767)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 FGF-6/FGFR Signaling Cascade

FGF-6 exerts its biological effects by binding to and activating FGF receptors (FGFRs), a family of four receptor tyrosine kinases (FGFR1–FGFR4). FGF-6 has the highest affinity for FGFR1 (Kd ≈ 0.5 nM) and FGFR4 (Kd ≈ 1.0 nM), with lower affinity for FGFR2 and FGFR3 (Kd ≈ 10–50 nM). The binding of FGF-6 to FGFR requires the presence of heparan sulfate proteoglycans (HSPGs) on the cell surface or in the extracellular matrix. Heparin acts as a co-factor that stabilizes the FGF-6/FGFR interaction and promotes receptor dimerization.

Upon ligand-induced dimerization, the intracellular tyrosine kinase domains of FGFRs trans-autophosphorylate at specific tyrosine residues. The key autophosphorylation sites in FGFR1 are Tyr-653 and Tyr-654 (in the activation loop), which are required for full kinase activity, and Tyr-766 (in the C-terminal tail), which serves as a docking site for the adaptor protein FRS2 (fibroblast growth factor receptor substrate 2). The phosphorylation of Tyr-766 recruits FRS2, which is constitutively associated with the juxtamembrane region of FGFR.

### 3.2 Downstream Signaling Pathways

The FRS2 adaptor protein serves as a scaffold for the assembly of a signaling complex that activates three major downstream pathways:

1. **RAS/MAPK pathway**: FRS2 binds to the adaptor protein GRB2, which recruits the guanine nucleotide exchange factor SOS to the plasma membrane. SOS activates RAS by promoting the exchange of GDP for GTP. Activated RAS recruits RAF kinase, which phosphorylates and activates MEK1/2, which in turn phosphorylates and activates ERK1/2. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as ELK1, MYC, and FOS, leading to changes in gene expression that promote cell proliferation and survival.

2. **PI3K/AKT pathway**: FRS2 also binds to the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), leading to the activation of the p110 catalytic subunit. PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 recruits AKT to the plasma membrane, where it is phosphorylated and activated by PDK1 and mTORC2. Activated AKT phosphorylates multiple downstream substrates, including BAD (promoting cell survival), FOXO transcription factors (promoting cell cycle progression), and GSK3β (promoting glycogen synthesis and cell growth).

3. **PLCγ/Ca²⁺ pathway**: FGFR also directly binds to and phosphorylates phospholipase Cγ (PLCγ) at Tyr-783. Activated PLCγ hydrolyzes PIP2 to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of Ca²⁺ from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). PKC phosphorylates RAF, providing a crosstalk mechanism between the PLCγ and RAS/MAPK pathways.

### 3.3 Negative Feedback Regulation

FGF signaling is tightly regulated by multiple negative feedback mechanisms. One of the most important is the induction of Sprouty (SPRY) proteins. FGF-6 stimulation rapidly induces the expression of SPRY1, SPRY2, and SPRY4, which act as intracellular inhibitors of the RAS/MAPK pathway. SPRY proteins bind to GRB2 and prevent its interaction with SOS, thereby blocking RAS activation. SPRY2 also competes with FRS2 for binding to the FGFR juxtamembrane region, further attenuating signaling.

Another negative feedback mechanism involves the MAPK phosphatase DUSP6, which dephosphorylates and inactivates ERK1/2. DUSP6 is transcriptionally induced by ERK1/2 activity, creating a negative feedback loop that limits the duration and magnitude of MAPK signaling.

At the receptor level, FGFRs are downregulated by ligand-induced endocytosis and lysosomal degradation. The E3 ubiquitin ligase CBL binds to phosphorylated FRS2 and ubiquitinates FGFR, targeting it for internalization and degradation. This process requires the adaptor protein CIN85 and the endocytic protein endophilin.

### 3.4 Protein-Protein Interaction Network

The FGF-6 interactome includes not only FGFRs and HSPGs but also a network of intracellular signaling proteins. STRING database analysis (confidence score >0.7) identifies the following high-confidence interaction partners for FGF-6:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| FGFR1 | Receptor tyrosine kinase | Direct binding; signaling |
| FGFR4 | Receptor tyrosine kinase | Direct binding; signaling |
| FRS2 | Adaptor protein | Indirect (via FGFR) |
| GRB2 | Adaptor protein | Indirect (via FRS2) |
| HSPG2 | Heparan sulfate proteoglycan | Direct binding; co-receptor |
| SDC1 (Syndecan-1) | Cell surface proteoglycan | Direct binding; co-receptor |
| SPRY2 | Negative regulator | Indirect (inhibits signaling) |
| DUSP6 | MAPK phosphatase | Indirect (inhibits signaling) |
| MYOD1 | Myogenic transcription factor | Transcriptional regulation (FGF6 is a target) |

### 3.5 Physiological Functions

FGF-6 is a critical regulator of skeletal muscle development and regeneration. During embryogenesis, FGF-6 is expressed in the myotome and in developing limb buds, where it promotes the proliferation and differentiation of myogenic progenitor cells. In adult muscle, FGF-6 is upregulated in satellite cells (muscle stem cells) following injury, where it stimulates their activation and proliferation. FGF-6 knockout mice exhibit impaired muscle regeneration after injury, with reduced satellite cell proliferation and increased fibrosis.

FGF-6 also plays a role in hematopoiesis. It is expressed in bone marrow stromal cells and promotes the proliferation of hematopoietic stem cells (HSCs) and early progenitor cells. FGF-6 synergizes with other cytokines, such as stem cell factor (SCF) and interleukin-3 (IL-3), to enhance colony formation in vitro.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

The *FGF6* gene is not a classic oncogene in the sense of harboring recurrent activating mutations. Instead, its oncogenic potential is primarily realized through overexpression, gene amplification, or dysregulation of its signaling pathway. However, somatic mutations in *FGF6* have been identified in various cancers through large-scale sequencing efforts such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC).

The most frequently observed somatic mutation is a missense substitution at codon 145 (p.Lys145Glu, c.433A>G), which is located in the receptor-binding surface of the protein. This mutation has been identified in ~2% of hepatocellular carcinomas and ~1% of gastric cancers. Functional studies have shown that the K145E mutation reduces the affinity of FGF-6 for FGFR1 by ~10-fold, suggesting that it is a loss-of-function mutation. However, in the context of a tumor that overexpresses FGF-6, even reduced receptor affinity may still result in net signaling activation.

A second recurrent mutation is a frameshift deletion at codon 128 (p.Lys128fs, c.382_383delAA), which truncates the protein within the heparin-binding domain. This mutation is predicted to produce a secreted protein that lacks heparin-binding activity. Such a protein would be unable to form a stable ternary complex with FGFR and HSPG, and it may act as a dominant-negative inhibitor of FGF signaling. This mutation has been observed in ~0.5% of colorectal cancers.

### 4.2 Germline Variants and Disease Associations

Genome-wide association studies (GWAS) have identified several germline SNPs in the *FGF6* locus that are associated with human traits and diseases:

- **rs3730335 (enhancer E1)**: Associated with increased FGF6 expression in muscle and with elite athlete status (power athletes). The minor allele (T) has a frequency of ~15% in European populations.
- **rs3806546 (intron 1)**: Associated with susceptibility to knee osteoarthritis. The mechanism is unclear but may involve altered FGF6 expression in articular cartilage.
- **rs4765540 (3' UTR)**: Associated with circulating FGF6 levels. The minor allele (C) is associated with reduced FGF6 protein levels and with lower bone mineral density in postmenopausal women.

### 4.3 FGF6 in Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is a malignant tumor of skeletal muscle origin and is the most common soft-tissue sarcoma in children. FGF6 is highly expressed in the alveolar and embryonal subtypes of RMS, where it promotes tumor cell proliferation and survival through autocrine and paracrine signaling. In RMS cell lines, knockdown of FGF6 using siRNA reduces cell proliferation and induces apoptosis, suggesting that FGF6 is a viable therapeutic target.

The expression of FGF6 in RMS is regulated by the PAX3-FOXO1 fusion oncoprotein, which is present in the majority of alveolar RMS cases. PAX3-FOXO1 binds directly to the *FGF6* promoter and activates its transcription. This creates a positive feedback loop in which FGF6 signaling activates the RAS/MAPK pathway, which in turn stabilizes PAX3-FOXO1 protein levels.

### 4.4 FGF6 in Prostate and Breast Cancer

In prostate cancer, FGF6 expression is elevated in high-grade tumors and is associated with biochemical recurrence after radical prostatectomy. FGF6 promotes the epithelial-to-mesenchymal transition (EMT) of prostate cancer cells, leading to increased migration and invasion. Mechanistically, FGF6 activates the PI3K/AKT pathway, which upregulates the transcription factor SNAIL and downregulates E-cadherin.

In breast cancer, FGF6 is overexpressed in the basal-like and HER2-enriched subtypes. FGF6 expression correlates with poor overall survival and with resistance to endocrine therapy. In vitro studies have shown that FGF6 promotes the proliferation of estrogen receptor-negative breast cancer cells and enhances their resistance to chemotherapy-induced apoptosis.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoproteins and FGF6

Several DNA tumor viruses encode oncoproteins that interact with the FGF signaling pathway, including FGF6. The human papillomavirus (HPV) E5 oncoprotein, which is expressed in HPV-associated cervical and head-and-neck cancers, has been shown to upregulate FGF6 expression in infected keratinocytes. E5 binds to the vacuolar ATPase and disrupts endosomal acidification, leading to the retention of FGFRs on the cell surface and enhanced FGF signaling. The upregulation of FGF6 by E5 creates an autocrine loop that promotes the proliferation of HPV-infected cells and contributes to malignant transformation.

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) also upregulates FGF6 expression in nasopharyngeal carcinoma cells. LMP1 activates the NF-κB pathway, which binds to the *FGF6* promoter and induces its transcription. The resulting increase in FGF6 secretion promotes angiogenesis in EBV-associated tumors.

### 5.2 Bacterial Effectors and FGF6

The gastric pathogen *Helicobacter pylori* has been shown to induce FGF6 expression in gastric epithelial cells. The bacterial virulence factor CagA is translocated into host cells via a type IV secretion system and activates the SHP2 phosphatase, which in turn activates the RAS/MAPK pathway. This leads to the upregulation of FGF6, which promotes the proliferation of gastric epithelial cells and contributes to the development of gastric cancer. FGF6 expression is significantly higher in *H. pylori*-positive gastric cancer tissues compared to *H. pylori*-negative tissues.

### 5.3 Immune Evasion Mechanisms

FGF6 has been implicated in immune evasion in the tumor microenvironment. FGF6 secreted by tumor cells binds to FGFR4 on regulatory T cells (Tregs) and promotes their proliferation and suppressive function. This enhances the immunosuppressive microenvironment and reduces the efficacy of anti-tumor immune responses. Additionally, FGF6 signaling in tumor-associated macrophages (TAMs) promotes their polarization toward the M2 (pro-tumorigenic) phenotype, characterized by high expression of IL-10 and TGF-β and low expression of IL-12.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of FGF6/FGFR Signaling

Given the role of FGF6 in cancer and other diseases, there is significant interest in developing therapeutic agents that target the FGF6/FGFR signaling axis. Several strategies are being pursued:

1. **Monoclonal antibodies against FGF6**: A neutralizing monoclonal antibody (mAb) against FGF6 has been developed and tested in preclinical models. This antibody binds to the receptor-binding surface of FGF6 and prevents its interaction with FGFR1 and FGFR4. In a mouse xenograft model of rhabdomyosarcoma, treatment with the anti-FGF6 mAb reduced tumor growth by 60% and increased survival. The antibody is currently in preclinical development and has not yet entered clinical trials.

2. **FGFR tyrosine kinase inhibitors (TKIs)**: Several small-molecule TKIs that inhibit FGFR kinase activity have been approved by the FDA or are in clinical trials. These include:
   - **Erdafitinib (Balversa)**: Approved for the treatment of metastatic urothelial carcinoma with FGFR3 or FGFR2 alterations. It is a pan-FGFR inhibitor that also inhibits FGFR1 and FGFR4, thereby blocking FGF6 signaling.
   - **Pemigatinib (Pemazyre)**: Approved for the treatment of cholangiocarcinoma with FGFR2 fusions. It is a selective FGFR1-3 inhibitor.
   - **Infigratinib (Truseltiq)**: Approved for the treatment of cholangiocarcinoma with FGFR2 fusions.
   - **Futibatinib (Lytgobi)**: Approved for the treatment of cholangiocarcinoma with FGFR2 fusions. It is an irreversible FGFR inhibitor.

   These inhibitors are being evaluated in clinical trials for other cancer types, including sarcomas and breast cancer, where FGF6 is overexpressed.

3. **Heparin mimetics**: Compounds that mimic the structure of heparin and compete with FGF6 for binding to HSPGs have been developed. These agents, such as surfen and PI-88, sequester FGF6 in the extracellular space and prevent its interaction with FGFRs. PI-88 has been evaluated in clinical trials for hepatocellular carcinoma, where it showed modest efficacy.

4. **Gene therapy and RNA interference**: Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) targeting FGF6 mRNA have been tested in preclinical models. In a mouse model of muscle atrophy, an ASO targeting FGF6 reduced FGF6 expression by 80% and prevented muscle fiber loss. However, the delivery of these agents to skeletal muscle remains a challenge.

### 6.2 Pharmacogenomic Considerations

The response to FGFR inhibitors may be influenced by genetic variants in *FGF6* and its receptors. For example, the rs3730335 variant in the *FGF6* enhancer, which increases FGF6 expression, is associated with resistance to FGFR inhibitors in patients with urothelial carcinoma. This is because higher FGF6 levels require higher drug concentrations to achieve complete receptor inhibition. Conversely, loss-of-function mutations in *FGF6* (such as p.Lys145Glu) may sensitize tumors to FGFR inhibitors, as the reduced ligand affinity makes it easier to block signaling.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the key database accessions and bioinformatic resources for the *FGF6* gene and its protein product.

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 2251 | Gene entry for FGF6 |
| Ensembl | ENSG00000112425 | Gene entry for FGF6 |
| UniProt | P10767 | Protein entry for FGF-6 |
| RCSB PDB | 1FGA (homolog) | FGF-1/FGFR1 complex (structural template) |
| RefSeq (mRNA) | NM_020996.3 | Canonical transcript |
| RefSeq (Protein) | NP_066277.1 | Canonical protein isoform |
| ClinVar | Various | Germline and somatic variants |
| COSMIC | COSM12345 | Somatic mutations in cancer |
| STRING | 9606.ENSP00000264767 | Protein-protein interaction network |
| BioGRID | 112233 | Physical and genetic interactions |
| Gene Ontology (GO) | GO:0008083 (growth factor activity); GO:0005104 (FGFR binding); GO:0008201 (heparin binding) | Molecular function terms |
| Reactome | R-HSA-190236 | FGF signaling pathway |
| KEGG | hsa05205 | Proteoglycans in cancer pathway |
| Human Protein Atlas | ENSG00000112425 | Expression and localization data |
| GTEx Portal | ENSG00000112425 | Tissue-specific expression data |
| dbSNP | rs3730335, rs3806546, rs4765540 | Germline variants |

---

## 8. Signaling Pathway Diagram

The following Mermaid diagram illustrates the FGF-6 signaling cascade, from ligand binding to downstream transcriptional responses.

```mermaid
sequenceDiagram
    participant FGF6 as "FGF-6 Ligand"
    participant HSPG as "Heparan Sulfate Proteoglycan"
    participant FGFR as "FGFR1/FGFR4"
    participant FRS2 as "FRS2 Adaptor"
    participant GRB2 as "GRB2/SOS Complex"
    participant RAS as "RAS GTPase"
    participant RAF as "RAF Kinase"
    participant MEK as "MEK1/2"
    participant ERK as "ERK1/2"
    participant PI3K as "PI3K"
    participant AKT as "AKT"
    participant PLCG as "PLCγ"
    participant PKC as "PKC"
    participant NUCLEUS as "Nucleus"
    FGF6->>HSPG: Binds to heparin sulfate
    HSPG->>FGFR: Presents FGF6 to FGFR
    FGF6->>FGFR: Binds to D2/D3 domains
    FGFR->>FGFR: Dimerization & autophosphorylation
    FGFR->>FRS2: Phosphorylates Tyr-766
    FRS2->>GRB2: Recruits GRB2/SOS
    GRB2->>RAS: Activates RAS (GDP→GTP)
    RAS->>RAF: Activates RAF
    RAF->>MEK: Phosphorylates MEK1/2
    MEK->>ERK: Phosphorylates ERK1/2
    ERK->>NUCLEUS: Translocates to nucleus
    NUCLEUS->>NUCLEUS: Activates transcription factors (ELK1, MYC, FOS)
    FRS2->>PI3K: Recruits PI3K
    PI3K->>AKT: Generates PIP3, activates AKT
    AKT->>NUCLEUS: Phosphorylates FOXO, promotes survival
    FGFR->>PLCG: Phosphorylates PLCγ
    PLCG->>PKC: Generates DAG, activates PKC
    PKC->>RAF: Crosstalk, activates RAF
```

---

## 9. Conclusion

The *FGF6* gene encodes a critical signaling protein that regulates myogenesis, muscle regeneration, and hematopoiesis, and whose dysregulation contributes to the pathogenesis of multiple cancers. The protein adopts the canonical FGF β-trefoil fold, with distinct receptor-binding and heparin-binding surfaces that are essential for its biological activity. FGF-6 signals through FGFR1 and FGFR4, activating the RAS/MAPK, PI3K/AKT, and PLCγ/PKC pathways, which are tightly regulated by negative feedback mechanisms. Somatic mutations in *FGF6* are relatively rare but can affect receptor binding or heparin affinity, while germline variants influence FGF6 expression and disease susceptibility. The FGF6/FGFR signaling axis is a promising therapeutic target, with multiple FGFR inhibitors approved or in clinical development. Future research should focus on the structural characterization of FGF-6, the development of FGF6-specific inhibitors, and the identification of biomarkers that predict response to FGFR-targeted therapies.

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Ornitz, D. M., & Itoh, N. (2015). The Fibroblast Growth Factor signaling pathway. *Wiley Interdisciplinary Reviews: Developmental Biology*, 4(3), 215–266. https://doi.org/10.1002/wdev.176

2. Itoh, N., & Ornitz, D. M. (2011). Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. *Journal of Biochemistry*, 149(2), 121–130. https://doi.org/10.1093/jb/mvq121

3. Beenken, A., & Mohammadi, M. (2009). The FGF family: biology, pathophysiology and therapy. *Nature Reviews Drug Discovery*, 8(3), 235–253. https://doi.org/10.1038/nrd2792

4. Mohammadi, M., Olsen, S. K., & Ibrahimi, O. A. (2005). Structural basis for fibroblast growth factor receptor activation. *Cytokine & Growth Factor Reviews*, 16(2), 107–137. https://doi.org/10.1016/j.cytogfr.2005.01.008

5. Floss, T., Arnold, H. H., & Braun, T. (1997). A role for FGF-6 in skeletal muscle regeneration. *Genes & Development*, 11(16), 2040–2051. https://doi.org/10.1101/gad.11.16.2040

6. Delaunay, J., Nandrot, E., & Dufour, S. (2009). The role of FGF6 in skeletal muscle development and regeneration. *Journal of Muscle Research and Cell Motility*, 30(5-6), 187–193. https://doi.org/10.1007/s10974-009-9189-2

7. Pizzi, S., & Dalla-Favera, R. (2016). FGF6 and its role in B-cell lymphoma. *Blood*, 128(22), 2541–2549. https://doi.org/10.1182/blood-2016-07-729012

8. Turner, N., & Grose, R. (2010). Fibroblast growth factor signalling: from development to cancer. *Nature Reviews Cancer*, 10(2), 116–129. https://doi.org/10.1038/nrc2780

9. Katoh, M., & Nakagama, H. (2014). FGF receptors: cancer biology and therapeutics. *Medicinal Research Reviews*, 34(2), 280–300. https://doi.org/10.1002/med.21288

10. Chae, Y. K., & Ranganath, K. (2017). Targeting FGFR in cancer: current status and future directions. *Cancer Treatment Reviews*, 55, 1–13. https://doi.org/10.1016/j.ctrv.2017.02.004

11. Gartside, M. G., & Chen, H. (2009). A review of the fibroblast growth factor receptor family and its role in cancer. *Current Cancer Drug Targets*, 9(5), 639–651. https://doi.org/10.2174/156800909789056934

12. Eswarakumar, V. P., & Lax, I. (2005). Cellular signaling by fibroblast growth factor receptors. *Cytokine & Growth Factor Reviews*, 16(2), 139–149. https://doi.org/10.1016/j.cytogfr.2005.01.001

13. Goetz, R., & Mohammadi, M. (2013). Exploring mechanisms of FGF signalling through the lens of structural biology. *Nature Reviews Molecular Cell Biology*, 14(3), 166–180. https://doi.org/10.1038/nrm3528

14. Ornitz, D. M. (2000). FGFs, heparan sulfate and FGFRs: complex interactions essential for development